Notably, the entire Scribfl/fl cohort had developed epidermal lesions at 14 weeks post-DMBA, while 43.7 % and 33.3 % of Scrib+/+ and Scrib+/fl cohorts respectively were tumor free (Fig. 5b). This evidence concerns the gene SCRIB and neoplasm.